Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Antifungal therapy with liposomal nystatin may reduce fever and neutropenia in
patients undergoing treatment for hematologic cancer. It is not yet known whether liposomal
nystatin is more effective than standard amphotericin B in treating patients with fever and
neutropenia who are receiving chemotherapy for hematologic cancer or bone marrow
transplantation for leukemia.
PURPOSE: Randomized phase III trial to study the effectiveness of liposomal nystatin compared
with standard amphotericin B to treat fever and neutropenia in patients receiving
chemotherapy for hematologic cancer or bone marrow transplantation for leukemia.
Phase:
Phase 3
Details
Lead Sponsor:
Aronex Pharmaceuticals
Treatments:
Amphotericin B Amphotericin B, deoxycholate drug combination Antifungal Agents Deoxycholic Acid Liposomal amphotericin B Miconazole Nystatin